Nogo isoforms (Nogo-A
migration ͉ angiogenesis ͉ reticulon ͉ vascular remodeling ͉ expression cloning N ogo isoforms are part of a superfamily of proteins called reticulons (1) . Nogo-A is a myelin-associated inhibitor of axonal sprouting, Nogo-B is expressed in many cells in culture and is the primary Nogo isoform expressed in blood vessels, and Nogo-C is expressed in the CNS and skeletal muscle (2) . Nogo-A and -B isoforms have a common amino terminus for the first 184 aa, and all three isoforms contain a conserved reticulon homology domain (RHD). A 66-aa loop domain termed Nogo-66 in the RHD can interact with a glycosylphosphatidylinositol-linked cell-surface Nogo-66 receptor (NgR) (3) , and this receptor mediates, in part, the inhibitory function of Nogo-A on neuronal outgrowth. In contrast to Nogo-A, the amino terminus of Nogo-B (AmNogo-B) promotes the adhesion and chemotaxis of endothelial cells and negatively regulates platelet-derived growth factor-induced chemotaxis in smooth muscle cells (4) . The receptor(s) mediating the actions of Nogo-B are unknown but are necessary to elucidate the potential functions of this ligand.
Here, we show that AmNogo-B binds to a previously uncharacterized Nogo-B receptor (NgBR). Structure-function analysis of the amino terminus of Nogo-A (AmNogo-A) and AmNogo-B defines the domains of Nogo-B necessary for binding to NgBR. NgBR colocalizes with the ligand Nogo-B during angiogenesis in vivo and mediates chemotaxis and 3D tube formation of endothelial cells in vitro. Thus, identification of this previously undescribed receptor may lead to the discovery of agonists or antagonists of this pathway to regulate vascular remodeling and angiogenesis.
Results and Discussion
Initially, we examined the migratory response of human umbilical vein endothelial cells (HUVEC) in response to a gradient of recombinant, purified alkaline phosphatase (AP) fusion protein expressing AmNogo-B (Fig. 1a , amino acids 1-200; APAmNogo-B) or a recombinant purified AmNogo-B (Fig. 1b) . AP alone or an AP fusion of Nogo-66 (AP-Nogo-66) does not promote HUVEC migration, but AmNogo-B dose-dependently increases migration of endothelial cells, similarly in magnitude to VEGF. Next, we examined the binding of AP-AmNogo-B to the surface of endothelial cells. As seen in Fig. 1 c and d , AP-AmNogo-B binds to a specific, saturable, high-affinity binding site on endothelial cells with an estimated K d of 9.7 nM. We have shown that the expression of NgR is below the limits of detection in vascular cells (4) . Thus, the ability of soluble AmNogo-B, but not Nogo-66, to induce chemotaxis and the specific binding of AP-AmNogo-B to endothelial cells suggests that AmNogo-B may interact with a unique receptor.
To identify a specific receptor for AmNogo-B, we used a recombinant AP-AmNogo-B fusion protein to screen a cDNA expression library from human heart (0.5 ϫ 10 6 independent clones) transfected into COS or CHO cells. Cells were transfected with pools (5,000 clones) of cDNA and screened by using AP versus APAmNogo-B binding and detection of the AP product by nearinfrared cell imaging (Li-Cor, Lincoln, NE) or AP activity assays. As seen in Fig. 2a (first column of wells, Upper and Lower), COS cells do not bind AP or AP-AmNogo-B but selectively bind AP-Nogo-66 when transfected with the cDNA encoding NgR (Fig.  2a Upper, second column). After several rounds of screening, amplification, and sib selection, a single cDNA was isolated and, when transfected into COS cells, afforded the binding of AmNogo-B (Fig. 2a Lower, second column) but not AP (Fig. 2a Upper, third column) or AP-Nogo-66 (Fig. 2a Lower, third column). The isolated cDNA (2,636 bp) encodes an ORF of 293 aa that we define as a NgBR (Fig. 2b) . The deduced amino acid sequence reveals a signal peptide sequence (23 aa) (Fig. 2b, underlined) , a putative ectodomain of 93 aa, and a Type 1A transmembrane domain of 19 aa (Fig 2b, doubly underlined) , followed by a cytoplasmic domain of 158 aa. Analysis of the NgBR cDNA sequence and translation product revealed 100% identity to a full-length sequence listed as a hypothetical protein in humans (BC013026.2 or NM138459.2) found on human chromosome 6q 22.31, with orthologs in mouse, chicken, and zebrafish. Comparing NgBR with other sequences in the National Center for Biotechnology Information database revealed that regions of the cytoplasmic domain have a high degree of similarity (49%) to the cis-prenyltransferase family of lipidmodifying enzymes, such as human cis-isoprenyltransferase and bacterial undecaprenyl phosphate synthase. However, direct assays for lipid transferase activity were negative (Fig. 6 , which is published as supporting information on the PNAS web site, with mouse liver as a positive control), suggesting that the NgBR may act as a scaffold for the binding of isoprenyl lipids and͞or prenylated proteins. Mechanistically, NgBR may signal via the recruitment͞ sequestration of prenylated proteins, such as Ras, joining the growing list of other proteins that use prenyl groups in proteins to facilitate binding to partners, such as prenylated Ras binding to galectin-1 (5, 6) or cGMP phosphodiesterase ␦ (7) and prenylated Cdc42 (8) or Rac2 (9)interacting with RhoGDI. However, additional studies are necessary to test this assertion.
Transient transfection of the NgBR cDNA into CHO cells allows the specific, saturable high-affinity binding similar to that seen in endothelial cells, with an estimated K d of 2.7 nM ( Fig. 2c and Inset). Moreover, purified AmNogo-B, dose-dependently displaces the binding of AP-AmNogo-B, consistent with these ligands competing for the same binding site (Fig. 2d) . Next, we examined the ability of the transfected receptor to bind AmNogo-B in vitro. Lysates prepared from vector or NgBR-hemagglutinin (HA)-transfected CHO (Fig. 2f ) .
Next, we characterized the regions of AmNogo-B responsible for binding to NgBR in cells stably expressing the receptor and HUVEC. AP, AP-Nogo-66 or AP-AmNogo-B (amino acids 1-180) did not bind to the receptor, whereas constructs expressing AP-Nogo-B (61-200) or full-length AP-Am Nogo-B did, suggesting that amino acids between 180 and 200 were critical for binding in NgBR-expressing cells (Fig. 3a) and in HUVEC (Fig. 3b) , but the stretch of aspartates and glutamates from amino acids 32-51 found in AmNogo-A and -B were not critical. Interestingly, amino acids 1-183 are identical between Nogo-A and -B (Fig. 3c) . In Nogo-A, there is a unique exon encoding amino acids 184-1,004, thereby generating a much longer amino terminus. Moreover, amino acids 1,005-1,019 in Nogo-A are identical to amino acids 186-200 in Nogo-B and to amino acids 12-26 in Nogo-C. Previous studies with AmNogo-A have identified two biologically active domains, amino acids 59-172, a region that reduces spreading of multiple cell types, and amino acids 544-725, a region that is neural-specific in reducing axon spreading. As seen in Fig. 3 d and e (in NgBR-expressing cells and HUVEC, respectively) AP-Nogo-A (59-172) and APNogo-A (544-725) do not bind to NgBR, suggesting that these ligands likely bind to a unique, unidentified receptor. In addition, constructs expressing several regions of Nogo-A overlapping with regions of identify in Nogo-B, as well as the amino terminus of Nogo-C (amino acids 1-26), do not bind to NgBR strongly, suggesting that the cloned receptor that expressed in HUVEC is specific for AmNogo-B as a ligand. However, we cannot rule out the possibility that NgBR may serve as a coreceptor for native fulllength Nogo-A.
Next, we developed a polyclonal Ab directed at the putative ectodomain of the receptor to examine the expression of NgBR in cells and tissue. CHO cells transfected with vector alone do not exhibit immunoreactivity, whereas CHO cells expressing a truncated form of NgBR lacking the cytoplasmic domain (missing amino acids 181-293; NgBR-CD) and WT NgBR yield the predicted molecular masses of 21 and 30 kDa, respectively (Fig. 4a) . NgBR protein is highly expressed in mouse heart, liver, kidney, and pancreas (Fig. 4b) . Next, because Nogo-B regulates vascular remodeling in vivo and promotes endothelial cell adhesion and migration in vitro, we examined the patterns of Nogo-B and NgBR in two models of angiogenesis: intradermal injection of adenoviral VEGF into the ear (Ad-VEGF) and healing of full-thickness wounds (Fig. 4c) . Nogo-B (Fig. 4c, column 1, red) and NgBR (Fig.  4c, column 2 , green) are present in both endothelial cells and pericytes in a subset of growing (day 3, Top) and more mature (day 14, Middle) angiogenic vessels. Immunoreactive Nogo-B and NgBR are found in a subset of PECAM-1-positive endothelial cells at both time points (Fig. 4c , see pink areas of colabeling in merge). In a different model of angiogenesis, Nogo-B and NgBR colocalize with PECAM-1-positive endothelial cells after 10 days of wound healing. Finally, to examine the topography of NgBR, we performed FACs analysis of CHO cells expressing vector alone [CHO-internal ribosome entry site (IRES)] or CHO cells stably expressing full-length NgBR with a C-terminal HA tag (CHO-NgBR-HA) (Fig. 4d) . As seen in Fig. 4d Upper, there is nonspecific labeling with all antibodies tested in both nonpermeabilized and permeabilized CHO-IRES cells. In contrast, as seen in Fig. 4d Lower, in nonpermeabilized cells expressing NgBR-HA, anti-NgBR detects a surface epitope (Fig. 4d Lower Left), and labeling with anti-HA is identical to nonimmune IgG control antisera, defining the N-terminal epitope on the cell surface. Permeabilization of the cells permitted detection of the C-terminal HA epitope, consistent with the To examine the function of NgBR, we examined AmNogo-Bmediated chemotaxis in CHO cells stably transfected with the cDNA for the NgBR. As seen in Fig. 5a , there is minimal binding of AP and AP-AmNogo-B to CHO cells, whereas stable transfection of CHO cells with the cDNA for NgBR permits binding of AP-AmNogo-B (see Fig. 5a Inset for levels of NgBR expressed). Next, CHO cells or CHO cells expressing NgBR were placed into a Boyden chamber and the chemotactic response to soluble AmNogo-B examined. As seen in Fig. 5b , transfection of NgBR is required for AmNogo-B-mediated chemotaxis, suggesting that the cloned receptor is essential for ligand binding and signal transduction. To examine the role of the endogenous receptor, we developed an RNA interference strategy [short interfering RNA (siRNA)] to reduce the expression of NgBR in cells. Sequence 1 (S1) targets the coding region of the mRNA and sequence 2 (S2) targets the 3Ј untranslated region (see Fig. 7 , which is published as supporting information on the PNAS web site, for characterization of siRNAs). Treatment of HUVEC with S2 siRNA but not nonsilencing (NS) RNA, reduces the levels of NgBR mRNA (determined by quantitative PCR; Fig. 5c ), NgBR protein (Fig. 5d) , the binding of AP-AmNogo-B (Fig. 5e) , and abolishes AmNogo-B-mediated chemotaxis of HUVEC (Fig. 5f ) . We also examined the effects of AmNogo-B in an in vitro model of tubulogenesis by placing HUVEC into 3D culture. AmNogo-B stimulated an increase in tube formation (phase-contrast images in Fig. 5g and quantified in Fig. 5h ), an effect attenuated by a reduction in NgBR by siRNA S2. These data document that endogenous NgBR is required for the in vitro angiogenic actions of AmNogo-B in endothelial cells.
These data define a signaling receptor for AmNogo-B that is expressed in a variety of tissues and in endothelial cells. Experiments showing that NgBR is necessary and sufficient for binding and migration in a heterologous expression system in CHO cells, as well as in native endothelial cells, demonstrate that the cloned cDNA is functionally competent to signal upon binding Nogo-B. We have demonstrated that Nogo-B is highly expressed in intact blood vessels, present in caveolae͞lipid rafts isolated from cultured endothelial cells, and exerts a role in vascular remodeling as an endogenous regulator of vascular cell functions after injury (4). Precisely how Nogo-A or -B ligands are released from cells is unknown, and this concept is complicated by many predicted and experimentally tested topographies of Nogo isoforms (4, 10 -12) but may occur because of low level expression on the cell surface or be released after injury or damage. Identification of how AmNogo-B couples to NgBR, and the development of agonists and͞or antagonists to block AmNogo-B-NgBR interaction will facilitate elucidating the contribution of Nogo-B͞NgBR to other cardiovascular functions. 
Materials and Methods
Cell Culture. HUVEC were cultured in M199 with 20%FBS and endothelial cell growth supplement (ECGS). HEK293T and COS-7 cells were cultured in high-glucose DMEM with 10% FBS. CHO cells were cultured in MEM-␣ with 5% FBS.
Real-Time RT-PCR. Total RNA from cells was isolated by using the RNeasy kit (Qiagen, Valencia, CA). Reverse transcription was then performed by using 100 ng of RNA and the Superscript First-Strand Synthesis System kit (Invitrogen). Real-time PCR analysis was done with the iCycler iQ detection system using the iQ SYBR green Supermix kit (Bio-Rad). The NgBR mRNA level was normalized by house keeping gene 18S. We used the following primers: for NgBR, forward (5Ј-TGCCAGTTAGTAGCCCAGAAGCAA-3Ј) and reverse (5Ј-TGATGTGCCAGGGAAGAAAGCCTA-3Ј); for 18S, forward (5Ј-CGGCGAC GACCCATTCGAAC-3Ј) and reverse (5Ј-GAATCGAACCCTGATTCCCC GTC-3Ј).
AmNogo-B Recombinant Proteins. To express AmNogo-B, the human Nogo-B cDNA of residues 1-200 was ligated into pcSecTag2-HygroC (Invitrogen) by using the Ig -chain signal peptide of pSecTag2 with an in-frame Myc-His tag or pcAP-5 in frame with the signal sequence, His tag, and placental AP coding region. The resultant plasmid DNA was transfected into HEK293T cells, and secreted AmNogo-B or AP-AmNogo-B was purified with Niaffinity chromatography.
AmNogo-B Receptor-Binding Assays and Expression Cloning. To detect AP-AmNogo-B binding, cultures were washed with Hanks' balanced salt solution (HBSS) containing 20 mM Hepes, pH 7.5, and 1 mg͞ml BSA (HBH). The plates were then incubated with AP-AmNogo-B in DMEM containing 20 mM Hepes, pH 7.5, and 1 mg͞ml BSA for 2 h at 4°C. The bound AP-AmNogo-B was detected by using the Blue Substrate kit (Vector Laboratories). The blue staining was examined by using the ODYSSEY Infrared Imaging System (Li-Cor, Lincoln, NE) and confirmed by microscopy. Alternatively, the bound AP-AmNogo-B was extracted with Triton X-100, and AP activity was colorimetrically quantified by using p-nitro-phenyl phosphate (Sigma) as substrate after heat inactivation of endogenous AP as described (13, 14) . Nonspecific binding was determined by measuring binding in the presence of a 100-fold molar excess of recombinant AmNogo-B lacking the AP fusion protein. Specific binding was determined by subtracting the nonspecific binding from total binding. For determination of apparent K d , the binding of AP-AmNogo-B was measured in triplicate as described above and the K d value quantified by using the Scatchard plot program of GraphPad PRISM (one-site binding, linear regression) using the ratio of bound ligand to free ligand as the y axis and bound ligand (pM) as the x axis.
For expression cloning of AmNogo-B receptor, pools of 5,000 arrayed clones from a human heart cDNA library (OriGene Technologies, Rockville, MD) were transfected into COS-7 cells, and AP-AmNogo-B binding was assessed. We isolated single NgBR cDNA clones by sib selection and sequenced them. A NgBR-HA was created in pIRESneo vector (BD, Palo Alto, CA) with HA tag at the carboxyl-terminal. To access the physical interaction of NgBR with AmNogo-B, we incubated 50 g of 
